Published in Health and Medicine Week, October 23rd, 2006
In contrast, increased levels of both lipid parameters were observed in patients taking efavirenz (Sustiva) combined with the same drugs.
The interim 24-week results are from an ongoing 48-week study in 198 treatment-naive HIV-infected patients, and were presented by Merck as a late breaker at the American Society for Microbiology's 46th annual International Conference on Antimicrobial Agents and Chemotherapy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week